The interview was filmed in preparation for an article in Oncology Times
BOSTON, MA—The risks of death from organ damage caused by COVID-19 infection have been quantified for each of a number of cardiovascular and other co-morbidities in an American analysis of data published in the New England Journal of Medicine from nearly 9,000 patients hospitalized for the coronavirus infection in three continents.
The impact on patient mortality has been assessed in a survey of 8910 patients from 169 hospitals in Asia, Europe, and North America.
First author Mandeep R. Mehra, MD MSc FRCP, the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and Executive Director of the Center for Advanced Heart Disease at Brigham and Women’s Hospital, who is also Professor of Medicine at Harvard Medical School and Editor-in-Chief of The Journal of Heart and Lung Transplantation, discussed the findings with Peter Goodwin, and explained how the researchers recognized COVID-19 as being just as much a cardiovascular disease as it was a respiratory disease.
The study found ACE-inhibition and angiotensin receptor blockade to be safe. Also ACE inhibitors and statin therapy appeared to bring better outcomes. Mehra described how COVID-19 disproportionately impacted patients with cardiovascular conditions, apparently by causing endothelialitis and inflammatory multi-organ damage in tissues as diverse as gut and neurones.